Filing Details
- Accession Number:
- 0001127602-23-017568
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-06-02 16:40:00
- Reporting Period:
- 2023-06-01
- Accepted Time:
- 2023-06-02 16:40:00
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1492422 | Apellis Pharmaceuticals Inc. | APLS | Pharmaceutical Preparations (2834) | 271537290 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1814304 | Karen Lewis | C/O Apellis Pharmaceuticals, Inc. 100 Fifth Avenue, 3Rd Floor Waltham MA 02451 | Chief People Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-06-01 | 5,000 | $34.11 | 46,504 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-06-01 | 5,000 | $86.00 | 41,504 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2023-06-01 | 5,000 | $0.00 | 5,000 | $34.11 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
106,000 | 2030-05-03 | No | 4 | M | Direct |
Footnotes
- This is a scheduled exercise and sale from an established 10b5-1 plan.
- This includes 74 shares from the 4/30/23 ESPP Purchase.
- This stock option was granted on 5/4/2020 and has a four year vesting period. 25% vest one year from grant date. The remaining 75% vest monthly over the last three years of the four year vesting period.